EMANUEU cMl'K3U, RUF S. GEHA, AND TALAL CHATM ABSTRACT. A 4-ysld female with severe combined immaaodefielency disease had sormrl numbers of T cells in her circulation and normal T a l l subsets. However, her T cells proliferated poorly to mitogem and dM not proliferate to antigens or to a n t i 0 3 MAb. IL-2 receptor expression was normal, but IL-2 synthesis was detectable. The addition of recombinant IL-2 to a mitogen-stimuhted caE ture resulted in normalization of the proliferative response. Northera blot analysis of total RNA derived from the patient's T cells revealed a weak or absent expression of mRNA coding for IG2, IL-3, IL-4, and IGS. In colltrast, there were normal amounts of mRNA coding for panulocyte-macrophage c o k m y~u l a t h g factor. Tumor necm sis factor and IL-6 pmducth were also normal. Nuclear rrrwn tramcriptbd assays revealed markedly decmsed levels of newly initiated nuclear tramcripts coding for IL-2, IL-3, IGq and IL-5 and normal levels of pandoqte macmpbage colony-stimulating factor trrnscripts in the patient relative to control lymphocytes. Gel retardation assays suggest that tbe NFAT We describe o case of primary severe combined immunodeficiency disease with normal n u m h and phenotypes of circulating lymphocytes that were deficient in their capacity to synthesize multiple lymphokines.
CASE REPORT
The patient, who is a girl, is 4 y 8 mo old and was born at 37 wk of gestation. At 2 mo of age, the patient developed a generalized vesicular eruption after exposure to a sibling with chicken 
RESULTS
Flow cytometric analysis of the patient's circulating lymphocytes at the age of 6 mo revealed normal absolute numbers and percentages of T cells that expressed the TCR/CD3 complex, CD4, and CD8. Despite their normal number and phenotype, the patient's lymphocytes failed to proliferate in response to the mitogenic a n t i 0 3 MAb OKT3 (Ortho Pharmaceutical Corp., Raritan, NJ) to a mitogenic combination of a n t i 0 2 MAb, OKTl1 + 9.6, or to phytohemagglutinin (Table 1) . Most importantly, as shown in Table 1 , the proliferative defect was corrected by the addition of recombinant L 2 . Table 2 demonstrates that mitogens induced the expression of the L 2 receptor on the patient's T cells, albeit to a lesser extent than that observed for control T cells. However, the secretion of L 2 by the patient's T cells upon their activation by agonistic antibodies was either severely defective or undetectable. This defective cytokine production was restricted to T cells and involved IFNy as well as L-2. In contrast, the monoqtederived cytokines, (lL-4, TNFa, and lL6) were produced nonnally ( Table 3 ).
The defective synthesis of multiple lymphokines by the patient's T cells could be the result of an abnormality aEccting the tramsductionviacdlsurfacenceptorsofiPnalJnecessaryforthe induction of lymphokine synthesis, e.g. elevation in fiee intracellular Ca2+, and activation of protein kinase C (4). Alternatively, the defective production of lymphokines by the patient's lymphocytes could have multed h m a more distal abnormality. Treatment of the patient's peripheral blood lymphocytes with the protein kinase C activator phorbol myristate acetate and the calcium ionophore ionomycin could induce only a modest synthesis of IG2, IFNy, and W. This suggested that the defective synthesis of lymphokines by the patient's peripheral blood T cells was related to an abnormality distal to the generation of Similar results were found in three other experiments.
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Tcdl lines stimulated with phorbd myriaate acetate at 20 aglmL rad 0.5 m M ionomycin for the indicated periods (in h). Ten pg of total cellular RNA per sample were M o n a t e d on 1 % agaroaelfddehyde gel, tmndemd to n i m u l o s e fibers, and probed for the remccth lymphokine, as described. GM-CSF, granulocytemacrophage colon) second messengers that follows the engagement of the TCR/CD3 stimulating fector. complex (5).
Tcell lines wen generated from the patient's peripheral lym-creased in the patient's T cells as compared to control lymphophocytes and wen similar to the patient's peripheral blood T cytes (6) T i 2). Thus, the defect in the patient's lymphocytes cells in their inability to secrete lymphokines upon stimulation involved a failure of initiation of lymphokiare gene transcription. with mitagnu NoPthern blot analysis of total cellular RNA The defect in the patient's lymphocytes likely involves an abnorisolated tiom tbe& cell lines upon activation with phorbol my-mality affecting a reguhtory Edctor that participates in the initiristate acetate and ionomycin revealed profound decmses in the ation of tmmaiption of these lymphokhm upon T-cdl activalevels of mRNA coding for L 2 , IL3, IL-4, IL5, and IFNq tion. with otherwise normal message size for each of thcse lymphoSeveral DNA regulatory elements govern the tmscription of kina (6) (Fii 1). nK time courses for lymphokinc mRNA l t 2 . These include NF-rB, AP-1,OCI'-1, awl NFAT-1 (Fii 3). accumulation in patient and in control lymphocytes wlert The migration of NFAT-1 camplex was fasts in the p & n t than tical. The spdicity of thcse abmmalities was mggaZd b@ ,<-in controls In contrast, -011 pP#gas of NF-sB, AP-1, and normal mRNA levels found for two other genes tnmsmi' bed b@--'OCT-l complexes wue ~m r d
The results mg$cst that the T cells, the cytokbe granukqtc--cdony4mdathi@9; patient's defect involved a dcfedve NFAT-l-bigdiqg complex. F@ 3. htein-binding sites on the regulatory region of IG2. improvement in her clinical status upon initiation of L 2 replacement therapy (3). Intemtingly, despite defective expression of multiple lymphokines, replacement therapy with IL2 alone was sufficient to restore her immune function. L 2 could u p regulate the production of some lymphokines that are defectively expressed by the patient's lymphocytes, e.g. IFN-. Indeed IG2 supplementation caused a modest increase in IFNy production by the patient's lymphocytes (data not shown). The hnction of other lymphokines such as L 3 is to a large extent redundant because of, its similarity to that of cytokines such as colonystimulating fktors (e.g. granulocytemacrophage colony-stimulating factor), the production of which was apparently unaffected. This would account for the normal hematopoiesis observed in this patient. form part of the NFAT complex. This may be important in the way the amount of L2driven expression is regulated, because there is a lot of AP-1 around. Very little is known about the structure of NFAT, but in addition to the nuclear and cytoplasmic components, which are in the 40-to 50-kD range, there is an additional component with a lower molecular mass of about 27 kD. From our gel retardation data, this patient shows a fast-migrating NFAT-1 complex, which suggests that a component of the complex is defective. Dr. G e l f . Are you s&g that this patient has both the cytoplasmic and the nuclear, but the association is abnormal?
Dr. Geha: Yes. If you look at 2 h, this patient's NFAT complex migrates identically to normal NFAT, but when you look at 4 and 8 h, the pattern changes. When we exchanged reagents with Dr. Crabtree, the position at which our patient's NFAT migrates at 4 and 8 h is the same abnormal position as his reconstituted nuclear plus cytoplasmic component. Thus, a third component of NFAT may be abnormal or unstable. Dr. Gelfand: I understand. So why couldn't the defect be at the level of the phosphatase that is responsible for the nuclear translocation?
Dr. Geha: In our study, we have taken the nuclear extract, so the cytoplasmic component, the putative target of the phosphatase, is already translocated to the nucleus.
Dr. Gelfand: But they fall off! Dr. Geha: That is true. So either there is a component that is falling off or maybe one of the two chains is unstable and breaks down. Dr. Gelfand: But the phosphate may be i d c i e n t and limiting?
Dr. Geha: Perhaps, but at 2 h the intensity of the NFAT complex in the nuclear extract is not bad at all. It is the position that falls off later.
Dr. Gelfand: In the cyclosporine effects, once you activate the cells to promote the initial regulation or transcription of IG2, cyclosporhe is no longer able to inhibit the subsequent transcrip tion. In a way, your case resembles this situation in that you have initial transcription. Dr. Geha: No. Phenotypically it looks like a cylcmporine defect but it is indeed a different defect. Phenotypically it looks as if this patient has been taking cyclosporhe so the NFAT-1 isn't working.
Dr. Gelfand: Have you tried to stimulate L 2 transcription through the other cyclosporine scxdled resistant pathway by taking PMA (phorbol myristate acetate) and anti-CD28 to deterinine whether or not NFAT is turned on appropriately or IL2 is turned on? Dr. Geha: No, we have not. But since in transfiection assays the CD28 effect on IL2 tmscription depends on an intact NF-AT element (but not vice versa) it is unlikely that anti-028 will comxt the defect. Note added in revision: No correction was obtained when anti-CD28 was tested.
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